Efficacy, tolerability and safety of nebivolol in patients with hypertension and diabetes: a post-marketing surveillance study

摘要

BACKGROUND AND OBJECTIVES: Hypertension is a widely prevalent condition of elevated blood pressure (BP) and is the leading risk factor for the development of cardiovascular disease (CVD). Many patients have additional risk factors such as diabetes mellitus (DM) or previous history of CVD. Nebivolol is a third-generation beta (β)-blockers which has been shown not to influence metabolic parameters in patients with DM. This post-marketing surveillance study aimed to collect information on the efficacy, safety and tolerability of nebivolol in hypertensive patients with concomitant DM. PATIENTS AND METHODS: Hypertensive patients with DM followed by 52 cardiologists, internal medicine specialists and general practitioners, between 24 August 2003 and 9 January 2007 in the Netherlands were included in this study. Physicians were asked to survey nebivolol treatment for 6 months. RESULTS: A total of 510 patients were enrolled. Overall, 93.3% of patients were diagnosed with essential hypertension and 6.7% with secondary hypertension. All patients were co-diagnosed with DM. Nebivolol therapy was associated with a significant reduction in both systolic blood pressure (BP) and diastolic BP versus baseline (p Conclusion: Nebivolol treatment was associated with a significantly reduced BP, improved blood glucose and LDL cholesterol levels and was well tolerated in hypertensive patients with concomitant DM. Corresponding Author: Luc M. Van Bortel, MD; e-mail: luc.vanbortel@UGent.be